The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).
 
Howard I. Scher
Honoraria - Chugai Pharma
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Celgene; Endo Pharmaceuticals; Endocyte; Exelixis; Ferring; Foundation Medicine; Genentech; Janssen; Medivation; OncologySTAT; Palmetto GBA; Pfizer; Sanofi; Takeda; Ventana Medical Systems; WIRB-Copernicus Group
Speakers' Bureau - WebMD
Research Funding - BIND Biosciences (Inst); Exelixis (Inst); Janssen (Inst); Janssen Diagnostics (Inst); Medivation (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Celgene; Endocyte; Exelixis; Ferring; Genentech; Janssen; Pfizer; Sanofi; Takeda; WIRB-Copernicus Group
 
Michael J. Morris
Consulting or Advisory Role - Astellas Pharma; Bayer; Millennium; Progenics
Research Funding - Agensys (Inst); Bayer (Inst); Janssen Oncology (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - fujifilm
 
Walter Michael Stadler
Honoraria - Bayer; CVS Caremark; Dendreon; Johnson & Johnson; medpacto; Merck; Millennium; Novartis; Roche/Genentech; Veridex
Consulting or Advisory Role - Bayer; CVS Caremark; Dendreon; Genentech/Roche; Medivation; medpacto; Millennium; Novartis; Sotio; Veridex
Research Funding - Active Biotech (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly/ImClone (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
Other Relationship - UpToDate
 
Celestia S. Higano
Employment - Cell Therapeutics (I)
Leadership - Cell Therapeutics (I)
Stock and Other Ownership Interests - Cell Therapeutics (I)
Consulting or Advisory Role - AbbVie; Bayer; BHR Pharma; Dendreon; Ferring; Genentech; Johnson & Johnson; Medivation; Orion; Pfizer; Sanofi
Research Funding - Algeta/Bayer (Inst); Aragon Pharmaceuticals (Inst); AstraZeneca (Inst); Dendreon (Inst); Emergent BioSolutions (Inst); Exelixis (Inst); Genentech (Inst); Medivation (Inst); Millennium (Inst); Oncogenex (Inst); Sanofi (Inst); Teva (Inst)
Travel, Accommodations, Expenses - AbbVie; Amgen; Astellas Pharma; Bayer; Dendreon; Ferring; Genentech; Johnson & Johnson; Medivation; Ockham; Orion; Pfizer; Sanofi; Teva
 
Susan Halabi
Consulting or Advisory Role - Bayer; Oncogenex; Sanofi
Travel, Accommodations, Expenses - Bayer
 
Matthew Raymond Smith
No Relationships to Disclose
 
Ethan M. Basch
No Relationships to Disclose
 
Karim Fizazi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Curevac; Dendreon; Ipsen; Janssen Oncology; Novartis; Orion; Sanofi; Takeda
Speakers' Bureau - Amgen; Astellas Pharma; Janssen Oncology; Sanofi
Travel, Accommodations, Expenses - Amgen
 
Charles J. Ryan
Honoraria - Astellas Pharma; Janssen Oncology
Consulting or Advisory Role - Bayer; Millennium
Research Funding - BIND Biosciences; Karyopharm Therapeutics; Novartis
 
Emmanuel S. Antonarakis
Honoraria - Dendreon; Janssen Biotech; Medivation; Sanofi
Consulting or Advisory Role - Dendreon; Janssen Biotech; Medivation; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Paul Gettys Corn
Honoraria - Sanofi
Consulting or Advisory Role - Sanofi
Travel, Accommodations, Expenses - Sanofi
 
Glenn Liu
Research Funding - Cellectar (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - I have patent pending titled "System and method for evaluation of disease burden" which provides a novel method to identify and quantitate treatment response. (Inst)
Other Relationship - Alliance HealthCare Services
 
Johann Sebastian De Bono
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Genentech/Roche; Sanofi
Research Funding - Arno Therapeutics (Inst); AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
 
Lawrence H. Schwartz
Honoraria - Merck KGaA; Pfizer
Patents, Royalties, Other Intellectual Property - Varian Medical Systems
Other Relationship - BioClinica; ICON Clinical Research
 
Tomasz M. Beer
Stock and Other Ownership Interests - Salarius Pharmaceuticals
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Janssen; Novartis; Sotio
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Research & Development (Inst); Medivation (Inst); OncoGenex (Inst); Sotio (Inst)
 
William Kevin Kelly
Consulting or Advisory Role - Sanofi
Research Funding - Novartis (Inst); Sanofi (Inst)
Other Relationship - Sanofi
 
Maha Hussain
Consulting or Advisory Role - Johnson & Johnson; Synthon
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Genentech (Inst); Medivation (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pa; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,7
 
A. Oliver Sartor
Consulting or Advisory Role - Astellas Pharma; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; Biscayne Pharmaceuticals; Johnson & Johnson; Medivation; Oncogenex; Sanofi; Teva; Tokai Pharmaceuticals
Research Funding - Bayer (Inst); Endocyte (Inst); Johnson & Johnson (Inst); Progenics (Inst); Sanofi (Inst); Sotio (Inst)
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Metamark Genetics
Consulting or Advisory Role - Amgen; Aragon Pharmaceuticals; Archimedes; Astellas Pharma; Auven Therapeutics; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Celgene; Dendreon; Endocyte; Exelixis; Genomic Health; GTx; Janssen; Medivation; Merck; Metamark Genetics; Millennium; MorphoSys; MTG Therapeutics; OncoCellMDX; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Sotio; Teva; Tokai Pharmaceuticals
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bavarian Nordic; BIND Biosciences; Janssen; Millennium; Progenics; Sanofi
 
Andrew J. Armstrong
Honoraria - Dendreon; Sanofi
Consulting or Advisory Role - Bayer; Dendreon; Janssen Biotech; Medivation; Novartis; Sanofi
Speakers' Bureau - Dendreon
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); ImClone Systems (Inst); Janssen Oncology (Inst); KangLaiTe (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Dendreon; Janssen Biotech; Medivation